[T-activin in the treatment of patients with recurrent erysipelas and concomitant eczema].
Increased levels of circulating immune complexes (CIC) have been revealed in 156 patients suffering from erysipelas and chronic eczema, 109 of these with frequent recurrences of erysipelatous inflammation, during all periods of the disease. The maximal rises of CIC levels have been associated with a combination of erysipelas relapse with eczema exacerbation, with the most pathogenic medium- and low-molecular complexes, making up together 80.4 +/- 4% of CICs, predominating in the blood. T-activin therapy results in an essential decrease of CIC level and in 2.5 times reduction of the number of early recurrences of erysipelas.
Frolov
V M
VM
Peresadin
N A
NA
Gaĭdash
I S
IS
Baskakov
I N
IN
Tishchenko
N A
NA
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000936:Antigen-Antibody Complex / Q000032:analysis; D002908:Chronic Disease; D004341:Drug Evaluation; D004485:Eczema / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D004886:Erysipelas / Q000188:drug therapy* / Q000209:etiology / Q000276:immunology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000627:therapeutic use*; D012008:Recurrence; D013949:Thymus Extracts / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000936:Antigen-Antibody Complex; D010455:Peptides; D013949:Thymus Extracts; C036191:T-activin
T-aktivin v lechenii bol'nykh retsidiviruiushcheĭ rozheĭ s soputstvuiushcheĭ ékzemoĭ.